Jane Street Group LLC Sells 20,134 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Jane Street Group LLC trimmed its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 89.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,308 shares of the medical instruments supplier's stock after selling 20,134 shares during the quarter. Jane Street Group LLC's holdings in Mesa Laboratories were worth $300,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. State Street Corp grew its position in Mesa Laboratories by 9.2% in the third quarter. State Street Corp now owns 214,148 shares of the medical instruments supplier's stock valued at $27,809,000 after acquiring an additional 18,128 shares during the period. Geneva Capital Management LLC grew its holdings in shares of Mesa Laboratories by 2.0% in the 3rd quarter. Geneva Capital Management LLC now owns 191,976 shares of the medical instruments supplier's stock worth $24,930,000 after purchasing an additional 3,732 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Mesa Laboratories by 10.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 165,955 shares of the medical instruments supplier's stock worth $19,722,000 after purchasing an additional 16,293 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Mesa Laboratories by 7.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier's stock valued at $11,444,000 after purchasing an additional 8,722 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Mesa Laboratories by 38.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 62,609 shares of the medical instruments supplier's stock valued at $8,130,000 after buying an additional 17,450 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Gary M. Owens sold 2,518 shares of Mesa Laboratories stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the completion of the transaction, the chief executive officer now directly owns 45,888 shares in the company, valued at approximately $5,213,794.56. The trade was a 5.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.40% of the company's stock.

Analyst Upgrades and Downgrades

MLAB has been the topic of a number of recent analyst reports. StockNews.com lowered Mesa Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, November 13th. Evercore ISI lifted their price objective on Mesa Laboratories from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st.

Mesa Laboratories Stock Down 5.4 %

Shares of MLAB stock traded down $7.64 during trading hours on Friday, hitting $134.39. 23,489 shares of the company were exchanged, compared to its average volume of 34,348. The company has a market capitalization of $729.87 million, a PE ratio of -2.95 and a beta of 0.82. Mesa Laboratories, Inc. has a 52 week low of $83.68 and a 52 week high of $147.34. The business has a 50 day moving average of $123.79 and a two-hundred day moving average of $119.91. The company has a current ratio of 0.70, a quick ratio of 0.51 and a debt-to-equity ratio of 0.65.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, February 28th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.64 annualized dividend and a dividend yield of 0.48%. Mesa Laboratories's dividend payout ratio is currently -1.40%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.